Ann: Appendix 3B and Notice Under Section 708A, page-2

	Column 1	Column 2	Column 3
0	2,036,444 Ordinary Shares -$0.053 per Ordinary Share 735,829 Ordinary Shares -$0.07 per Ordinary Share
1	6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of Options

Exercising of Options, from the resolution on the 14th of Nov 17.


PS : from....

https://www.********/investing/2018/05/06/3-reasons-regeneron-stock-could-start-climbing-aga.aspx

.."As one of the first new eczema treatments for patients that aren't satisfied with topical steroids, Dupixent sales hit an annualized run rate of $556 million during its third quarter after earning approval in the U.S. That isn't nearly as fast as analysts had been predicted, but it still appears capable of generating more than $4 billion annually at its peak. .."
Nice little earner